Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.

NCT02101684 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment rate

Conditions

Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

Interventions

DRUG: Orteronel 300mg BID

Sponsor

Grupo Español de Tumores Huérfanos e Infrecuentes

Collaborators

[object Object]